EarningsQ2 2026 Earnings Report
MX:ROVIN Q2 2026 EPS Results
Actual EPS$29.88
Consensus EPS―
Beat/Miss―
One Year Ago EPS$8.62
MX:ROVIN Q2 2026 Revenue Results
Actual Revenue$3.91B
Expected Revenue$3.63B
Beat/MissBeat by +$281.26M
YoY Revenue Growth+20.02%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeBefore Open
Conference CallThursday, July 23, 2026
MX:ROVIN Upcoming Earnings
Laboratorios Farmaceuticos Rovi's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and financial positives (double‑digit revenue growth, 38% CDMO growth, improved gross margins, strong cash generation, strategic Phoenix acquisition and clinical progress) alongside material caveats: much of the headline profit uplift was driven by a one‑off EUR 62.4 million badwill, underlying EBITDA and EBIT declined year‑on‑year, SG&A and R&D rose sharply, and the heparin franchise still faces year‑on‑year declines despite recent Q2 improvement. Management maintained cautious full‑year guidance and flagged regulatory and contract timing risks. Overall the results show meaningful momentum in CDMO, cash flow and product development, but underlying operational profitability and cost pressures temper the outlook.Company Guidance
Total Revenue Growth
Total revenue increased 13% year‑on‑year to EUR 357.0 million in H1 2026; operating revenue rose 9% to EUR 344.2 million, driven mainly by CDMO strength.
CDMO Business Acceleration
Contract manufacturing (CDMO) revenue grew 38% to EUR 106.3 million in H1 2026, supported by restored capacity at Madrid and contribution from the Phoenix facility (EUR 13.8 million revenue from Phoenix in the period).
Improved Gross Profit and Margin
Gross profit increased 21% to EUR 237.1 million; gross margin improved by 6.5 percentage points to 68.9% (and excluding other income improved 3.0 pp to 65.2%), aided by CDMO mix, Okedi contribution and lower heparin raw material costs.
Phoenix Acquisition and One‑off Gain
Acquired injectable manufacturing facility in Phoenix (April 1); preliminary purchase price allocation generated a EUR 62.4 million bargain purchase gain (badwill) recorded as nonrecurring income, strengthening U.S. industrial footprint.
Strong Cash Generation and Net Cash Position
Operating cash flow increased to EUR 94.3 million (H1 2025: EUR 28.0 million); free cash flow rose to EUR 64.7 million (H1 2025: EUR 7.5 million). Gross cash EUR 130.2 million vs total debt EUR 107.7 million, resulting in net cash of EUR 22.5 million (vs net debt EUR 21.9 million at YE25).
Net Profit Increase (Including One‑off)
Net profit reached EUR 84.4 million, up 113% year‑on‑year, primarily reflecting the nonrecurring badwill and favorable tax treatment of that item (effective tax rate 16.9% vs 20% prior year).
Specialty Product Momentum — Okedi
Okedi sales of EUR 34.0 million, up 27% year‑on‑year; management reiterates potential longer‑term peak sales target of EUR 100–200 million and reports broad uptake across multiple European markets.
Clinical Progress on ISM Platform
Letrozole SIE received FDA clearance to proceed with IND clinical investigations and Phase III recruitment expected to start in Q3 2026; Risperidone QUAR delivered strong Phase I results and is progressing to Phase II with enrollment expected in Q4 2026.
Heparin Franchise Stabilization Signs
Management improved outlook for low molecular weight heparins (LMWH): expected decline revised from high single‑digit to mid single‑digit for 2026; bemiparin international sales recovered strongly in Q2 (up 52% vs Q2 2025 and >3x vs Q1 2026) and bemiparin expected to grow low single‑digit for full year.
MX:ROVIN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed